Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Ruzzi

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Cancers|April 14, 2019
Cancer Vaccines Co-Targeting HER2/Neu and IGF1RCarla De Giovanni, Lorena Landuzzi, Arianna Palladini, et al.
Cell Communication and Signaling : CCS|October 11, 2024
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?Francesca Ruzzi, Chiara Cappello, Maria Sofia Semprini, et al.
Journal of Cell Communication and Signaling|November 11, 2024
CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscapeMichela Pasello, Maria Antonella Laginestra, Maria Cristina Manara, et al.
Frontiers in Pharmacology|December 1, 2025
Development of cellular models expressing cynomolgus (<i>Macaca fascicularis</i>) HER2 for the functional evaluation of cross-reactive anti-human HER2 responseChiara Cappello, Francesca Ruzzi, Julia Consoli, et al.
Journal of Hematology & Oncology|October 12, 2022
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortalityCarlo Sorrentino, Luigi D'Antonio, Stefania Livia Ciummo, et al.
Biological Research|March 28, 2026
Alternatives for fetal bovine serum (FBS) and sustainability of milk derivatives in cell cultureOlga Maria Pittino, Maria Sofia Semprini, , et al.
Cancer Letters|July 2, 2026
Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing SarcomaMarianna Carrabotta, Maria Cristina Manara, Lorena Landuzzi, et al.
Journal of Translational Medicine|January 30, 2025
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinomaLaura Scalambra, Francesca Ruzzi, Olga Maria Pittino, et al.
Oncogenesis|November 14, 2021
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progressionVeronica Giusti, Francesca Ruzzi, Lorena Landuzzi, et al.
Translational Lung Cancer Research|December 15, 2022
ADK-VR2, a cell line derived from a treatment-naïve patient with <i>SDC4-ROS1</i> fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLCFrancesca Ruzzi, Stefania Angelicola, Lorena Landuzzi, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Cancers|April 14, 2019
Cancer Vaccines Co-Targeting HER2/Neu and IGF1RCarla De Giovanni, Lorena Landuzzi, Arianna Palladini, et al.
Cell Communication and Signaling : CCS|October 11, 2024
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?Francesca Ruzzi, Chiara Cappello, Maria Sofia Semprini, et al.
Journal of Cell Communication and Signaling|November 11, 2024
CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscapeMichela Pasello, Maria Antonella Laginestra, Maria Cristina Manara, et al.
Frontiers in Pharmacology|December 1, 2025
Development of cellular models expressing cynomolgus (<i>Macaca fascicularis</i>) HER2 for the functional evaluation of cross-reactive anti-human HER2 responseChiara Cappello, Francesca Ruzzi, Julia Consoli, et al.
Journal of Hematology & Oncology|October 12, 2022
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortalityCarlo Sorrentino, Luigi D'Antonio, Stefania Livia Ciummo, et al.
Biological Research|March 28, 2026
Alternatives for fetal bovine serum (FBS) and sustainability of milk derivatives in cell cultureOlga Maria Pittino, Maria Sofia Semprini, , et al.
Cancer Letters|July 2, 2026
Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing SarcomaMarianna Carrabotta, Maria Cristina Manara, Lorena Landuzzi, et al.
Journal of Translational Medicine|January 30, 2025
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinomaLaura Scalambra, Francesca Ruzzi, Olga Maria Pittino, et al.
Oncogenesis|November 14, 2021
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progressionVeronica Giusti, Francesca Ruzzi, Lorena Landuzzi, et al.
Translational Lung Cancer Research|December 15, 2022
ADK-VR2, a cell line derived from a treatment-naïve patient with <i>SDC4-ROS1</i> fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLCFrancesca Ruzzi, Stefania Angelicola, Lorena Landuzzi, et al.
Pageof 4